The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials

被引:29
作者
Roumen, Frans J. M. E. [1 ]
机构
[1] Atrium Med Ctr, Dept Obstet & Gynecol, NL-6401 CX Heerlen, Netherlands
关键词
acceptability; contraceptive pill; cycle control; pharmacology; randomised controlled trials; vaginal ring;
D O I
10.1016/j.contraception.2007.01.013
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: The purpose of this review was to compare pharmacology, contraceptive efficacy, cycle control, side effects and acceptability with the combined contraceptive vaginal ring (CCVR) and combined oral contraceptives (COCs). Study Design: All randomized controlled trials (RCTs) between the CCVR and a COC up to and including December 2006 were analyzed. Results: Twelve RCTs comparing the CCVR and a COC were identified. Systemic exposure to ethinyl estradiol (EE) with the CC`VR was half of that with a 30-mu g EE-containing COC with less variation in serum levels. During CCVR use, sex hormone-binding globulin and cortisol-binding globulin concentrations were significantly less increased than during COC use. Both methods showed adequate ovarian suppression and equal contraceptive efficacy. Uterine concentrations of EE and etonogestrel were not elevated with the CCVR. Cycle control achieved with the CCVR was better than that of the COC. Compliance with both methods was high. Mean blood pressure and body weight did not change in either group. Incidence of adverse events such as breast tenderness, headache and nausea was comparable, but a higher incidence of local and ring-related events led to higher discontinuation rates in the CCVR group. Both contraceptives were highly acceptable and resulted in a global improvement of sexual function. Ring users were more likely to continue with their method after study completion than COC users. Conclusions: The vaginal ring has the same contraceptive efficacy as COCs with lower systemic EE exposure, more consistent serum EE levels and better cycle control, but more local adverse events resulting in higher discontinuation rates. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:420 / 429
页数:10
相关论文
共 21 条
  • [1] Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone
    Ahrendt, Hans-Joachim
    Nisand, Israel
    Bastianelli, Carlo
    Gomez, Maria Angeles
    Gemzell-Danielsson, Kristina
    Urdl, Wolfgang
    Karskov, Birgit
    Oeyen, Luc
    Bitzer, Johannes
    Page, Geert
    Milsom, Ian
    [J]. CONTRACEPTION, 2006, 74 (06) : 451 - 457
  • [2] Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring
    Dieben, TOM
    Roumen, FJME
    Apter, D
    [J]. OBSTETRICS AND GYNECOLOGY, 2002, 100 (03) : 585 - 593
  • [3] A comparative study on the effects of a contraceptive vaginal ring NuvaRing® and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function
    Duijkers, I
    Killick, S
    Bigrigg, A
    Dieben, TOM
    [J]. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2004, 9 (03) : 131 - 140
  • [4] Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study
    Duijkers, IJM
    Klipping, C
    Verhoeven, CHJ
    Dieben, TOM
    [J]. HUMAN REPRODUCTION, 2004, 19 (11) : 2668 - 2673
  • [5] Follicular growth during contraceptive pill or vaginal ring treatment depends on the day of ovulation in the pretreatment cycle
    Duijkers, IJM
    Verhoeven, CHJ
    Dieben, TOM
    Klipping, C
    [J]. HUMAN REPRODUCTION, 2004, 19 (11) : 2674 - 2679
  • [6] Contraceptive vaginal ring therapy has fewer adverse metabolic effects than an oral pill
    Elkind-Hirsch, Karen E.
    Darensbourg, Carmen
    Ogden, Beverly
    Ogden, Lauren
    Hindelang, Philip
    [J]. OBSTETRICS AND GYNECOLOGY, 2006, 107 (04) : 16S - 16S
  • [7] Effects of two types of hormonal contraception - oral versus intravaginal - on the sexual life of women and their partners
    Guida, M
    Sardo, AD
    Bramante, S
    Sparice, S
    Acunzo, G
    Tommaselli, GA
    Di Carlo, C
    Pellicano, M
    Greco, E
    Nappi, C
    [J]. HUMAN REPRODUCTION, 2005, 20 (04) : 1100 - 1106
  • [8] Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 μg ethinyl estradiol and 3 mg drospirenone
    Milsom, I.
    Lete, I.
    Bjertnaes, A.
    Rokstad, K.
    Lindh, I.
    Gruber, C. J.
    Birkhaeuser, M. H.
    Aubeny, E.
    Knudsen, T.
    Bastianelli, C.
    [J]. HUMAN REPRODUCTION, 2006, 21 (09) : 2304 - 2311
  • [9] Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition
    Mulders, TMT
    Dieben, TOM
    [J]. FERTILITY AND STERILITY, 2001, 75 (05) : 865 - 870
  • [10] Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive
    O'Connell, KJ
    Osborne, LM
    Westhoff, C
    [J]. CONTRACEPTION, 2005, 72 (05) : 323 - 327